About Cantabio Pharmaceuticals
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
The company was founded in Palo Alto, California in 2009 as Gardedam Therapeutics in order to pursue novel drug discovery research to develop pharmacological chaperones targeting a number of proteins linked to Alzheimer’s and Parkinson’s disease. The companies’ R&D was strengthened with an initial partnership with Dr. C. Rochet at Purdue University and Novalix and Gardedam was awarded two separate grants in collaboration with Dr. Rochet in 2010 and 2013 by the Michael J. Fox Foundation in support of its DJ-1 therapeutic project. Cantabio Pharmaceuticals, Inc. was established through the merger of Gardedam Therapeutics with Cantabio Pharmaceuticals in November of 2015.
Cantabio Pharmaceuticals conducts in house R&D on critical elements of its drug discovery pipeline, while forming strategic alliances around novel technologies and outsourcing generic research activities to established contract research organizations. Cantabio has operations in Palo Alto (USA), Cambridge (UK) and Budapest (Hungary) where the company carries out in-house R&D in wet laboratory facilities. This balance of out-sourced and in-house R&D capabilities has enabled Cantabio to maintain high levels of operational efficiency and highly effective use of funds, while ensuring development and operation of key technologies in-house.
The Neurodegenerative Disease market is huge (over $17 billion) and is in continuous growth as human lifespan increases and the baby boomer generation grows older.
Our leadership team first came together while studying for the Executive MBA at the Judge Business School, University of Cambridge. Each member boasts impressive experience, coupling successful scientific, academic and business achievements and wide ranging industry experience.